Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

PARAG N PATEL

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1598976235
CMS profile
722264
Location
FLEMINGTON, NJ

General Payments · PY2018–2024

$4,449.72

  • Reported across 234 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$722.04

33 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $722.04 33

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $183.31 5
GENZYME CORPORATION $153.15 6
ITI, Inc. $103.01 6
GlaxoSmithKline, LLC. $84.26 5
IDORSIA PHARMACEUTICALS US INC $50.57 3
Ardelyx, Inc. $39.70 2
CVRx Inc. $22.93 1
Stryker Corporation $22.58 1
Abbott Laboratories $19.41 1
Kaleo, Inc. $15.15 1
OptiNose US, Inc. $14.35 1
Amgen Inc. $13.62 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $652.93 30
PY2019 $498.00 31
PY2020 $729.50 38
PY2021 $729.41 38
PY2022 $701.67 41
PY2023 $416.17 23
PY2024 $722.04 33

Payment records · PY2024 (33)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Abbott Laboratories $19.41 03/15/2024 Food and Beverage Undisputed 01/23/2026 1125146986 CMS
Amgen Inc. $13.62 03/13/2024 Food and Beverage Undisputed 01/23/2026 1115999102 CMS
Ardelyx, Inc. $20.52 10/17/2024 Food and Beverage Undisputed 01/23/2026 1146700140 CMS
Ardelyx, Inc. $19.18 11/12/2024 Food and Beverage Undisputed 01/23/2026 1146700142 CMS
AstraZeneca Pharmaceuticals LP $15.72 01/18/2024 Food and Beverage Undisputed 01/23/2026 1104545418 CMS
AstraZeneca Pharmaceuticals LP $13.10 02/14/2024 Food and Beverage Undisputed 01/23/2026 1104756140 CMS
AstraZeneca Pharmaceuticals LP $13.35 02/21/2024 Food and Beverage Undisputed 01/23/2026 1105684021 CMS
AstraZeneca Pharmaceuticals LP $16.37 07/25/2024 Food and Beverage Undisputed 01/23/2026 1105604541 CMS
AstraZeneca Pharmaceuticals LP $124.77 11/07/2024 Food and Beverage Undisputed 01/23/2026 1105391902 CMS
CVRx, Inc. $22.93 07/15/2024 Food and Beverage Undisputed 01/23/2026 1133856340 CMS
GENZYME CORPORATION $9.31 01/24/2024 Food and Beverage Undisputed 01/23/2026 1139741436 CMS
GENZYME CORPORATION $6.21 02/07/2024 Food and Beverage Undisputed 01/23/2026 1139741438 CMS
GENZYME CORPORATION $8.68 04/24/2024 Food and Beverage Undisputed 01/23/2026 1139741462 CMS
GENZYME CORPORATION $7.42 05/20/2024 Food and Beverage Undisputed 01/23/2026 1139741480 CMS
GENZYME CORPORATION $115.04 09/26/2024 Food and Beverage Undisputed 01/23/2026 1139741602 CMS
GENZYME CORPORATION $6.49 10/30/2024 Food and Beverage Undisputed 01/23/2026 1139741548 CMS
GlaxoSmithKline, LLC. $16.67 03/14/2024 Food and Beverage Undisputed 01/23/2026 1116109959 CMS
GlaxoSmithKline, LLC. $17.11 03/19/2024 Food and Beverage Undisputed 01/23/2026 1116527378 CMS
GlaxoSmithKline, LLC. $16.34 04/10/2024 Food and Beverage Undisputed 01/23/2026 1115823969 CMS
GlaxoSmithKline, LLC. $16.15 05/17/2024 Food and Beverage Undisputed 01/23/2026 1116310375 CMS
GlaxoSmithKline, LLC. $17.99 10/17/2024 Food and Beverage Undisputed 01/23/2026 1116342122 CMS
IDORSIA PHARMACEUTICALS US INC $17.45 01/02/2024 Food and Beverage Undisputed 01/23/2026 1146761051 CMS
IDORSIA PHARMACEUTICALS US INC $16.56 09/28/2024 Food and Beverage Undisputed 01/23/2026 1146757822 CMS
IDORSIA PHARMACEUTICALS US INC $16.56 10/26/2024 Food and Beverage Undisputed 01/23/2026 1146758306 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $16.11 04/16/2024 Food and Beverage Undisputed 01/23/2026 1143293573 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $18.13 05/31/2024 Food and Beverage Undisputed 01/23/2026 1143293577 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $16.57 07/09/2024 Food and Beverage Undisputed 01/23/2026 1143293580 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $17.40 08/21/2024 Food and Beverage Undisputed 01/23/2026 1143293584 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $17.40 10/11/2024 Food and Beverage Undisputed 01/23/2026 1143293587 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $17.40 11/20/2024 Food and Beverage Undisputed 01/23/2026 1143293591 CMS
kaleo, Inc. $15.15 06/17/2024 Food and Beverage Undisputed 01/23/2026 1126628786 CMS
Optinose US, Inc. $14.35 08/07/2024 Food and Beverage Undisputed 01/23/2026 1142174810 CMS
Stryker Corporation $22.58 02/26/2024 Food and Beverage Undisputed 01/23/2026 1119941538 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.